Press Release

Biocon Limited announced that its partner, Duopharma Biotech Berhad, secured multiple insulin contracts valued over MYR 225 million from the Ministry of Health, Malaysia. Biocon's Malaysian subsidiary, Biocon Sdn. Bhd., will supply various insulin products including recombinant human insulin, insulin glargine, and insulin aspart under these contracts, which include a three-year agreement for human insulin (~MYR 155.27 million) and two 2-year agreements for insulin glargine (~MYR 18 million) and insulin aspart (~MYR 52.5 million). This reinforces Biocon's long-standing commitment and presence in Malaysia's diabetes care market.